COMPARISON OF THE PATIENTS AFFECTED WITH RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA VIRUS: A SINGLE-CENTER PROSPECTIVE OBSERVATIONAL STUDY IN JAPAN

Respirology ◽  
2017 ◽  
Vol 22 ◽  
pp. 209-209
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Observational Study ◽  
Prospective Observational Study ◽  
Single Center ◽  
Influenza Virus A ◽  
Syncytial Virus

scholarly journals Evaluation of the Cepheid Respiratory Syncytial Virus and Influenza Virus A/B real-time PCR analyte specific reagent

2009 ◽  
Vol 162 (1-2) ◽  
pp. 88-90 ◽  
Author(s):  
Andrew D. Sails ◽  
David Saunders ◽  
Stephanie Airs ◽  
David Roberts ◽  
Gary Eltringham ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Real Time ◽  
Real Time Pcr ◽  
Influenza Virus A ◽  
Syncytial Virus ◽  
Specific Reagent

Differential Airway Inflammatory Responses in Asthma Exacerbations Induced by Respiratory Syncytial Virus and Influenza Virus A

2013 ◽  
Vol 161 (4) ◽  
pp. 378-382 ◽  
Author(s):  
Hiroto Matsuse ◽  
Tomoko Tsuchida ◽  
Susumu Fukahori ◽  
Tetsuya Kawano ◽  
Shinya Tomari ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Inflammatory Responses ◽  
Influenza Virus A ◽  
Asthma Exacerbations ◽  
Syncytial Virus

scholarly journals Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus

Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 234
Author(s):  
Sarah Al-Beltagi ◽  
Cristian Alexandru Preda ◽  
Leah V. Goulding ◽  
Joe James ◽  
Juan Pu ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Respiratory Syncytial Virus ◽  
Influenza A Virus ◽  
Broad Spectrum ◽  
Influenza A ◽  
Respiratory Viruses ◽  
Influenza Viruses ◽  
Virus Challenge ◽  
2009 H1n1 ◽  
Syncytial Virus

The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to include antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for any disease bears testament to the challenges of antiviral development. We recently showed that non-cytotoxic levels of thapsigargin (TG), an inhibitor of the sarcoplasmic/endoplasmic reticulum (ER) Ca2+ ATPase pump, induces a potent host innate immune antiviral response that blocks influenza A virus replication. Here we show that TG is also highly effective in blocking the replication of respiratory syncytial virus (RSV), common cold coronavirus OC43, SARS-CoV-2 and influenza A virus in immortalized or primary human cells. TG’s antiviral performance was significantly better than remdesivir and ribavirin in their respective inhibition of OC43 and RSV. Notably, TG was just as inhibitory to coronaviruses (OC43 and SARS-CoV-2) and influenza viruses (USSR H1N1 and pdm 2009 H1N1) in separate infections as in co-infections. Post-infection oral gavage of acid-stable TG protected mice against a lethal influenza virus challenge. Together with its ability to inhibit the different viruses before or during active infection, and with an antiviral duration of at least 48 h post-TG exposure, we propose that TG (or its derivatives) is a promising broad-spectrum inhibitor against SARS-CoV-2, OC43, RSV and influenza virus.

Sign in / Sign up

Export Citation Format

Share Document